Clinical Trial

A Trial of Nimotuzumab and Pinkiller Efficacy and Pain in Advanced Head and Neck Squamous Cell Carcinoma

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 17, 2025 (before its estimated April 14, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to investigate the impact of combining Nimotuzumab with analgesic agents on pain management outcomes, as well as the effectiveness and safety profile of this therapeutic combination in the comprehensive treatment of locally advanced head and neck squamous cell carcinoma.
Trial Details
NCT Number NCT06879691
Lead Sponsor Biotech Pharmaceutical Co., Ltd.
Collaborators: Baotou Cancer Hospital
Conditions Head and Neck Cancer
Enrollment 171 participants
Start Date 2021-05-15
Primary Completion 2025-04-14 (estimated)
Study Completion 2025-04-14 (estimated)
Updated on ClinicalTrials.gov 2025-03-17